U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers Draft Guidance for Industry April 2022

Draft Level 1 Guidance

Not for implementation. Contains non-binding recommendations.

This guidance is being distributed for comment purposes only.

Submit Comments by

Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2021-D-1268


Docket Number:
FDA-2021-D-1268
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research
Center for Devices and Radiological Health
Center for Food Safety and Applied Nutrition
Center for Tobacco Products
Office of Regulatory Affairs
Center for Veterinary Medicine

This guidance provides information to sponsors and nonclinical laboratories regarding the use and management of whole slide images used during histopathology assessment and/or pathology  peer review performed for good laboratory practice (GLP)-compliant nonclinical toxicology  studies using non-human specimens.2 When whole slide imaging is used as part of a nonclinical 20 study conducted in compliance with the GLP regulations, adequate documentation is critical. The  FDA’s expectations regarding documentation practices during generation, use, and retention of  whole slide images have not been clearly defined and vary among nonclinical testing facilities. This question-and-answer document is intended to clarify FDA’s recommendations concerning  the management, documentation, and use of whole slide imaging in histopathology assessment  and/or pathology peer review for nonclinical studies conducted in compliance with the GLP  regulations.

Back to Top